10.01.2022 | Letter to the Editor
Response to the Letter on “The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus”
verfasst von:
Bertram Pitt, Gabriel Steg, Lawrence A. Leiter, Deepak L. Bhatt
Erschienen in:
Cardiovascular Drugs and Therapy
|
Ausgabe 3/2022
Einloggen, um Zugang zu erhalten
Excerpt
We thank the authors of the letter (DTY-D-21-00785R1) for their interest in our work [
1]. As pointed out, the correct reference for the finding of a significant reduction in the incidence of stroke and myocardial infarction (MI) associated with the use of the SGLT1/2 inhibitor sotagliflozin is from the SCORED trial [
2] rather than from the SOLOIST trial [
3]. We agree that the significant reductions in MI and in stroke (as well as in heart failure) with sotagliflozin were proven in patients with type 2 diabetes mellitus and chronic kidney disease in SCORED and that the significant reduction in heart failure with sotagliflozin in SOLOIST was proven in patients with acute worsening heart failure, but we believe that these benefits may extend to other patients beyond those specifically studied in the trials. However, future trials will be necessary to evaluate sotagliflozin’s effect on cardiovascular outcomes in patients without diabetes—in those with or without chronic kidney disease and with or without heart failure. …
